Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Glyxambi 25 mg/5 mg Film-coated Tablets

{email} Notify me of changes to this product

emc account functionality

Sign in or register for an emc account to use this functionality and much more:

  • Get the latest updates to your inbox

    Receive email notifications when chosen products are updated

  • Stay up to date with document change history

    Get full access to document change history

  • Similar product search

    Use active ingredient, company or ATC code

  • Save your regular searches

    Simple access to search enquiries every time you need them

  • Favourite products you use most often

    Helps you find products you use regularly as fast as possible

Active Ingredient:
empagliflozin , linagliptin
Company:  
Boehringer Ingelheim Limited See contact details
ATC code: 
A10BD19
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Safety Alert
{arrow_left}
{arrow_right}
SGLT2 inhibitors: advice on the risk of diabetic ketoacidosis (MHRA release April 2016)

Test for raised ketones in patients with ketoacidosis symptoms, even if plasma glucose levels are near-normal.

Further information can be found in the MHRA Drug Safety Update


SGLT2 inhibitors: advice on increased risk of lower-limb amputation (mainly toes) (MHRA release March 2017)

Canagliflozin may increase the risk of lower-limb amputation (mainly toes) in patients with type 2 diabetes. Evidence does not show an increased risk for dapagliflozin and empagliflozin, but the risk may be a class effect. Preventive foot care is important for all patients with diabetes.

Further information can be found in the MHRA Drug Safety Update


SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum) (MHRA release February 2019)

If Fournier’s gangrene is suspected, stop the SGLT2 inhibitor and start treatment urgently (including antibiotics and surgical debridement). Fournier’s gangrene is a rare but potentially life-threatening infection that requires urgent medical attention.

Further information can be found in the MHRA Drug Safety Update


SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness (MHRA release March 2020)


SGLT2 inhibitor treatment should be interrupted in patients who are hospitalised for major surgical procedures or acute serious medical illnesses and ketone levels measured, preferably in blood rather than urine. Treatment may be restarted when the ketone values are normal and the patient's condition has stabilised.

Further information can be found in the MHRA Drug Safety Update
Boehringer Ingelheim Limited
Company image
Address
Ellesfield Avenue, Bracknell, Berkshire, RG12 8YS
Telephone
+44 (0)1344 424 600
WWW
http://www.boehringer-ingelheim.co.uk
Medical Information Direct Line
+44 (0)1344 742579
Medical Information e-mail
[email protected]